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Abstract 
Objective: Alpha-synuclein protein aggregates and mitochondrial dysfunction have both been 
described in substantia nigra neurons from patients with idiopathic Parkinson’s disease and 
dementia with Lewy bodies. We explored the relationship between alpha-synuclein pathology 
and mitochondrial respiratory chain protein levels within single substantia nigra neurons. 
Design: We examined alpha-synuclein and mitochondrial protein expression in substantia 
nigra neurons of eight patients with dementia with Lewy bodies, five patients with 
Parkinson’s disease, and eight controls. Protein expression was determined using 
immunocytochemistry followed by densometric analysis. 
Subjects: We examined single substantia nigra neurons from five patients with iPD (mean age 
81.2 years), eight patients with DLB (mean age 75 years) and eight neurologically and 
pathologically normal controls (mean age 74.5 years). The control cases showed minimal 
Lewy body pathology and cell loss. Patients with DLB and iPD fulfilled the clinical and 
neuropathological criteria for these diseases. 
Results: Our results show that mitochondrial density is the same in nigral neurons with and 
without alpha-synuclein pathology. However, there are significantly higher levels of the 
respiratory chain subunits in neurons containing alpha-synuclein pathology.  
Conclusion: The finding of increased levels of respiratory chain complex subunits within 
neurons containing alpha-synuclein does not support a direct association between 
mitochondrial respiratory chain dysfunction and the formation of alpha-synuclein pathology.  
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Introduction 
The pathogenesis of idiopathic Parkinson’s disease (iPD) and Dementia with Lewy bodies 
(DLB) remains unclear. Mitochondrial involvement has been identified as important by 
several lines of evidence. Defects of the mitochondrial respiratory chain, in particular in 
activity of complex I, have been described in homogenised substantia nigra (SN) from 
patients with iPD (1, 2). High levels deleted mitochondrial DNA (mtDNA) have been 
reported in the SN of elderly controls and Lewy body disease patients (LBD) (3, 4). Finally,  
genes encoding proteins which affect mitochondrial function have been identified  in families 
with autosomal recessive juvenile parkinsonism (5) including PARK2 (parkin) [MIM 
602544], PARK6 (pink1) [MIM 608309] and PARK7 (DJ-1) [MIM 602533]. These genes 
have varied roles within mitochondria, including  targeting of mitochondria to autophagy (6, 
7), protection against oxidative stress (7, 8) and reactive oxygen species (ROS) 
sensing/scavenging (9, 10).  
 
Whilst mitochondrial dysfunction has a key role to play in the pathogenesis of iPD and DLB, 
its relationship with the other key pathogenic factor, the accumulation of alpha-synuclein, is 
less well understood. The accumulation of alpha-synuclein as filamentous inclusions in 
neurons (Lewy bodies, LBs), and in dystrophic neurites, is the pathological hallmark of both 
iPD and DLB. In autosomal recessive parkinsonism homozygous mutations generally result 
in nigral degeneration not associated with LB pathology (5), although LB pathology has been 
reported in a compound heterozygous individual carrying pink1 mutations (11) and in 
individuals carrying heterozygous mutations in parkin and pink1 genes (12-14).  
 
Recent studies suggest that alpha-synuclein and mitochondria may have closer interactions 
than once thought and their interaction in vitro coincides with mitochondrial dysfunction (15, 
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16). However, much of this data comes from studies examining this relationship in 
homogenised SN tissue (17) or overexpressing cell culture systems (17-19) rather than in 
single human neurons. To test whether mitochondrial abnormalities influence alpha-
synuclein accumulation we studied individual neurons from the SN in LBD cases. 
 
 
Patients and methods 
Formalin-fixed, paraffin-embedded (FFPE) upper midbrain tissue from five iPD patients  
(mean age 81.2 years; range 75-87 years; mean PM delay 52.3 hours; mean tissue fixation 2.8 
months), eight DLB patients  (mean age 75 years; range 70-81 years; mean PM delay 39 
hours; mean tissue fixation 1.9 months) and eight neurologically and pathologically normal 
controls (mean age 74.5 years; range 58-87 years; mean PM delay 30.6 hours; mean tissue 
fixation 1.55 months) were included. Control cases showed minimal Lewy body pathology 
(however one case showed occasional LBs, Lewy neurites and fine granular inclusions) and 
no cell loss (0/4 (0-25% cell loss)). Patients with DLB and iPD fulfilled the clinical and 
neuropathological criteria for these diseases (
Tissue 
20). The use of all human tissue had been 
consented to by the appropriate Local Research Ethics Committee and conformed to the UK 
MRC Guidelines on the use of tissue in medical research.  
 
Single immunohistochemistry (IHC) for alpha-synuclein (Figure 1 A-D) and mitochondrial 
markers (Figure 1 E & F) has been performed previously (
Immunohistochemistry 
21). A dual IHC assay was 
designed combining staining for alpha-synuclein with the detection of a mitochondrial 
protein (Figure 1, G and 2, A & G). We used antibodies to specific subunits of  respiratory 
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chain complexes I, II and IV and detection of an outer membrane mitochondrial protein, 
porin, as a marker of mitochondrial density.  
 
Immunocytochemistry was performed according to (22) with minor modifications. Antigen 
retrieval was performed in concentrated formic acid followed by high temperature retrieval in 
1mM EDTA, pH 8.0 before blocking with 1% normal goat serum. The alpha-synuclein 
primary antibody (1:30) was then applied for 90 minutes (clone KM51, Novocastra, Leica 
Biosystems, UK). Biotinylated goat anti-mouse antibodies (Vector Labs, UK) were applied, 
followed by Vectastain Elite ABC (Vector Labs, UK) and Vectastain Novared substrate 
(Vector Labs, UK). Following this step sections were stored in TBS overnight at 4ºC. 
Immunocytochemistry for mitochondrial proteins (supplementary table 1) was then 
performed with detection of primary antibodies using the polymer detection system 
(Menapath kit, A. Menarini Diagnostics, UK).  
 
Dual IHC stained sections were analysed using bright field microscopy and Nuance 
multispectral imaging (Cri, Woburn, MA). We took low magnification (x4) images of the 
SN, defined its boundaries and took 15 random images of neuromelanin containing neurons 
within this area. By using single stain controls for each of the chromogens used in the IHC 
protocol (Figure 1 J-M); individual spectra for each colour can be created using the Nuance 
software. Due to the nature of the SN neurons we generated spectra for four ‘chromogens’, 
blue for haematoxylin, red for alpha-synuclein, purple for the mitochondrial proteins and 
yellow/brown for the neuromelanin. These spectra can then be applied to the dual stained 
sections and the signal from all the component chromogens can be extracted (
Imaging and densitometric analysis 
23). The 
Nuance software generates black and white images for all the component chromogens and a 
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pseudo coloured composite image (figure 2). The black and white images can then be used 
for densitometric analysis.  
 
For each pigmented neuron we measured the intensity of mitochondrial protein staining (per 
unit area), and assessed the type/amount of alpha-synuclein pathology. Mitochondrial protein 
signals were sampled from a region of the neuron not containing neuromelanin, alpha-
synuclein or the nucleus. Densitometric analysis is an inverse linear scale ranging from 0 
(black) to 250 (white). Values were inverted by subtraction from 250, so that more intense 
staining gave a higher value. All densitometry values were normalised to the mean control 
value for each protein studied, calculated for cells stained in the same batch. Normalisation 
was performed by expressing each data point from LBD cases stained at the same time as a 
percentage of the control mean for that particular protein.  
 
To minimize variation in intensity of immunostaining, we performed staining using one 
antibody for all patients and controls on the same day, where possible. We also compared 
porin immunostaining in neurons with no pathology for both controls and patients and 
showed no difference between the mean values obtained for controls and patients 
(supplementary figure 1). Therefore it was reasonable to compare all the data from the LBD 
cases to the controls and to assume that any changes seen were not due to technical variation. 
 
The data sets were not normally distributed and we used a Mann Whitney U test to compare 
mitochondrial protein staining in neurons with and without pathology. To ascertain whether 
the staining intensities for mitochondrial proteins changed between different pathology types 
we performed a Bartlett's test for equal variances and the Kruskal-Wallis test. To investigate 
Statistics 
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the number of cells which were deficient for certain mitochondrial respiratory chain proteins 
in cases and controls, using densometric analysis and without assigning arbitrary ranges we 
defined deficient cells as those with a staining intensity falling below the 10th percentile value 
for the control data for each protein. To determine if there was a difference between cells 
with and without pathology we performed a Fisher’s exact test.  
 
Results 
Method validation 
Absolute quantification of protein expression through the use of densitometric analysis is 
difficult, but is the only approach allowing us to look at expression in neurons within the 
same section and compared to controls. Several publications have shown that antibodies to 
several respiratory chain complexes (including those used in this paper) can detect changes 
which correlate with a biochemical defect (22, 24, 25).  In addition, we have used the same 
method to explore protein expression in patients with neurodegeneration secondary to 
primary defects of the mitochondrial genome and are able to show clear defects of protein 
expression in neurons which correlate with the biochemical defect seen (supplementary 
figure 2).   
 
Mitochondrial protein levels in SN neurons of normal controls 
Using brain sections from normal control subjects we measured the normal expression of 
different mitochondrial proteins in 5298 single pigmented SN neurons (supplementary figure 
3). There was minimal evidence of LBs and alpha-synuclein aggregates in these subjects 
(6.5% of cells contained pathology), this was much lower than in iPD and DLB cases (29% 
of cells contained pathology (1433/4947 neurons). There was wide variation of staining 
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intensities in normal control individuals for all six mitochondrial proteins studied in this 
investigation.  
 
Mitochondrial protein levels in SN neurons with and without pathological alpha-synuclein 
aggregates  
 
The data obtained from both iPD and DLB cases showed the same results, and since iPD and 
DLB are postulated to be on a clinical spectrum (20) we pooled all the data from these cases 
to ensure robust statistical significance. From this point forward LBD refers to any data from 
both iPD and DLB cases. We analysed a total of 4947 single SN neurons from LBD cases.   
 
Porin immunohistochemistry showed that the median and range of the relative mitochondrial 
density were equal in neurons with and without alpha-synuclein pathology in LBD cases (p 
value = 0.36) (Figure 3A). Therefore any differences in intensity of respiratory chain subunit 
staining between neurons with and without pathology were unlikely due to changes in overall 
mitochondrial mass. Staining for complex II 70kDa showed a slight increase in cells with 
pathology (p value = 0.05) but this was less significant than for other proteins studied. This is 
relevant since complex II is the only complex of the electron transport chain which contains 
no subunits encoded by mtDNA. The staining intensity for this subunit is not affect by 
defects of mtDNA and in fact forms the basis of our COX/SDH activity assay (26).  
 
For all other mitochondrial respiratory chain proteins studied (CI19, CI20, COXI and 
COXIV), the median intensity of staining was significantly greater in those cells containing 
alpha-synuclein pathology than in those without (p value =<0.0001) (Figure 3). Results for 
both complex I subunits show that a large number of the cells without pathology have very 
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low expression of complex I subunits, entirely compatible with previous reports of reduced 
activity of complex I in ageing substantia nigra (27) (Figure 3B). This difference in staining 
intensities between neurons with and without pathology was also seen for complex IV. The 
result for COXI is particularly relevant since immunohistochemistry for this respiratory chain 
subunit has been shown to correlate with complex IV activity (22). These results suggest that 
respiratory dysfunction is not directly involved in the formation of alpha-synuclein 
aggregates (Figure 3C).  
 
This pattern of staining is similar for all patients (Figure 4). Most patients (with the exception 
of LBD6) show an increase of staining for mitochondrial complex I 19kDa subunit in neurons 
containing alpha-synuclein pathology compared to those devoid of pathology. This further 
validates our observation since the staining intensities of neurons of a single case are the 
same as when we consider the whole group. 
 
Relationship of type of alpha-synuclein pathology to expression of mitochondrial proteins 
To examine the relationship between the expression of mitochondrial proteins and the extent 
of alpha-synuclein pathology, we graded the density of alpha-synuclein staining as: few 
granules (+/-), granules or a small pre Lewy body (+), larger pre Lewy body (++) and finally 
very dense pre-Lewy or large Lewy body (+++) (28, 29). The only statistical differences 
between data sets occurred when considering the staining for CI19 (Figure 5A) and porin 
(between + vs +++ and ++ vs +++ (p value=<0.05)).  For all other mitochondrial proteins 
there was no statistical difference (p value=>0.05) (Figure 5B, e.g. COXI). From these results 
it appears that in individual SN neurons increased levels of expression of the majority of 
mitochondrial proteins is not related to the progression of alpha-synuclein aggregates from 
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granules to Lewy bodies, and is certainly not as dramatic as that observed between cells with 
and without pathology.  
 
Complex I deficiency in pigmented LBD SN 
Since previous data suggests a role for complex I deficiency in PD, we determined the 
number of neurons which were deficient for complex I subunits (figure 6).  In normal aged 
substantia nigra 9.94% (36/362) of neurons are deficient for CI20, while 9.85% are deficient 
for CI19. In LBD we determined that 18.0% (66/366) of neurons containing no pathology are 
deficient for CI19, while only 0.9% (1/107) of neurons containing alpha-synuclein pathology 
are deficient (p value=<0.00001).  For CI20 10.4% (31/298) of all LBD cells containing no 
pathology are deficient, compared to only 1.5% (2/126) of alpha-synuclein containing 
neurons (p value=<0.00001). Thus very few neurons containing alpha-synuclein pathology 
are deficient for complex I subunits and that deficiency occurs predominantly in neurons 
which do not contain pathology. 
 
Discussion 
Our data shows that within individual nigral neurons the presence of pathological alpha-
synuclein aggregates is associated with significantly higher expression of respiratory chain 
subunits. Alpha-synuclein pathology and deficiencies of mitochondrial respiratory chain 
subunits, two factors thought to play important roles in the pathogenesis of synucleinopathies, 
appear to affect different populations of nigral neurons. 
 
Although we only studied protein expression levels in fixed tissues, the expression of a 
number of the selected proteins reflects the activity of respiratory chain complexes within 
mitochondria (22). We had expected that mitochondrial dysfunction would lead directly to 
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alpha-synuclein pathology. A deficiency of mitochondrial respiratory chain subunits could 
lead to ATP depletion which would impair a number of cellular processes, including protein 
degradation through both chaperone mediated autophagy and the ubiquitin proteasome 
system (UPS) (30) . Defects of mitochondrial respiratory chain subunits can cause increased 
free radical production in cell culture (31-34) and could potentially lead to damage of 
intracellular proteins and increased load on the proteasome.  
 
There are a number of potential explanations for why cells containing alpha synuclein 
pathology appear to have increased expression of mitochondrial respiratory chain proteins, 
with no increase in overall mitochondrial density, we discuss three of them. Firstly, it is 
feasible that mitochondrial dysfunction and alpha-synuclein accumulation provide a toxic 
‘double-hit’ for neurons. Those cells showing both severe mitochondrial dysfunction and 
alpha-synuclein accumulation are lost, thus explaining why it is extremely rare to find cells 
with both low levels of mitochondrial protein expression and alpha-synuclein pathology. 
However, data from this study examining the relationship between different stages of alpha 
synuclein accumulation and mitochondrial dysfunction would not support this.  
 
A second possibility is that normal mitochondrial function is required for the accumulation of 
alpha-synuclein into Lewy bodies. Aggregating protein needs to be transported along 
axons/neurites to the cell body where it is proposed that it accumulates into aggresomes, 
which eventually form Lewy bodies. Recruitment of mitochondria and UPS proteins then 
occurs facilitating the clearance and degradation of aggregating protein (35). The transport 
and clearance of alpha-synuclein will require mitochondrial ATP and thus can only occur in 
cells with normal mitochondrial function. A situation may then arise whereby alpha-
synuclein clearance cannot cope with the increased levels of aggregating protein and the 
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Lewy body forms. In this context the observation of little or no alpha-synuclein pathology in 
the respiratory chain deficient SN neurons would seem entirely fitting.  
 
A final consideration is the type of alpha-synuclein being investigated. There still remains 
some debate as to which of the alpha-synuclein forms is potentially toxic. Alpha-synuclein 
can exist in many forms some of which have the ability to interact with lipid membranes and 
may cause the formation of pores within them. We have only examined insoluble forms of 
alpha-synuclein and it is possible that it is these forms which are less harmful. In neurons 
damaged alpha-synuclein forms soluble oligomers and protofibrils, which have been shown 
to damage membranes and have other detrimental effects. Neurons which show 
mitochondrial dysfunction may be unable to aggregate these toxic forms of alpha-synuclein. 
Again it could potentially be the same ‘double hit’ hypothesis as mentioned above of 
increased toxic alpha-synuclein and mitochondrial dysfunction leading to cell death. Neurons 
with normal mitochondrial function may be better equipped to respond to the toxic alpha-
synuclein species and bring them together into a LB, thus protecting the cell from the 
damaging effects of soluble forms of this protein. Alpha-synuclein is believed to have 
detrimental influences on mitochondrial function but again the form of alpha-synuclein 
responsible remains undecided (18, 36). 
 
While many previous studies have found an association between mitochondrial dysfunction 
and the accumulation of alpha-synuclein in homogenised tissue, our data shows that at the 
single cell level these two pathologies seem not to occur in the same cells. The data presented 
in this paper shows that while mitochondrial dysfunction and alpha-synuclein pathology are 
important in LBD, mitochondrial dysfunction appears not to be the catalyst for alpha-
synuclein accumulation at the single cell level.  
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Figure legends. 
(Parts A-D) Different stages of alpha-synuclein accumulation/aggregation in SN. (Part A) 
Punctate alpha-synuclein granules (arrowheads), (Part B) Irregular inclusion/pre Lewy body 
(arrowhead), (Part C) single Lewy body (arrow) (Part D) multiple Lewy bodies (arrow). (Part 
E) Some SN neurons are deficient for mitochondrial complex I subunits (arrow), in the other 
neuron mitochondrial protein staining is very punctate representing the mitochondria and is 
absent from the nucleus; single IHC for CI20 (purple), haematoxylin (blue), neuromelanin 
(yellow/brown). (Part F) All nigral neurons show equal levels of porin; single IHC for porin 
(control section) (purple), haematoxylin (blue), neuromelanin (yellow/brown). (Part G) SN 
neurons showing different stages of alpha-synuclein accumulation/aggregation and variable 
degree of deficiency for mitochondrial COXI subunit; granular alpha-synuclein pathology 
(red arrow), larger and denser pathology (black arrow) and deficiency for COXI in the neuron 
lacking any alpha-synuclein pathology (arrowhead). (Part H) SN neuron stained using dual 
IHC for alpha-synuclein with the omission of the primary antibody for the mitochondrial 
proteins. (I) SN neuron stained using dual IHC for mitochondrial protein (porin) with the 
omission of the primary antibody for alpha-synuclein.  (Parts J-M) single 
immunohistochemistry controls for each of the chromogens used in this study; (Part J) 
haematoxylin (blue), (Part K) alpha-synuclein (red), (Part L) mitochondrial protein (porin, 
purple) (Part M) neuromelanin (yellow/brown). Scale bars represent 20µm. Images captured 
at x40 magnification  
Figure 1. Bright field images of single and dual IHC 
 
Figure 2. Separation of signals from individual chromogens on dual IHC tissue using 
multispectral imaging. 
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Parts A & B; Bright field images of double IHC for alpha synuclein and mitochondrial 
proteins. (A) CI20 and (B) porin staining in neurons with alpha-synuclein pathology (black 
arrows) and neurons without alpha-synuclein pathology (red arrows). Parts C & D; 
Composite images generated by the Nuance system from the unmixed images of signal from 
each chromogen. Note the images are identical to A & B with positive signals from 
mitochondrial protein (purple) and alpha-synuclein (red) appearing as in the bright field 
image. Parts E & F; Signal from the purple chromogen (wavelength 455-500nm) labelling the 
mitochondrial protein (E-CI20, F porin); note mitochondrial staining is localised in the 
neuronal cytoplasm and surrounding neuropil but is absent from the nucleus (* E, * F). Parts 
G & H; Signal from the red chromogen (wavelength 500-525nm) labelling the alpha-
synuclein aggregates; note that the alpha-synuclein staining is very specific and is only 
detected in those neurons containing pathology (black arrows), the nuance software does not 
give a signal for alpha-synuclein in the neuron without pathology (red arrow). Parts I & J; 
Signal from the yellow/brown chromogen of neuromelanin (wavelength 420-440nm); note 
that the neuromelanin signal is very specific and appears granular in these unmixed images 
identical to its appearance in the bright field image. Parts K & L; Signal from the blue 
chromogen of haematoxylin (wavelength 565-600nm). All images captured at x40 
magnification 
 
 
 There is significant increase in the levels of several mitochondrial RC proteins in neurons 
containing pathology, although the density of mitochondria (porin) and CII70 staining is 
uniform. Part A: Staining intensities per unit area for porin (neurons without pathology 
Figure 3. Mitochondrial protein staining is increased in SN neurons with alpha-synuclein 
pathology. 
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(NWOP), 25% percentile 104.8, median 120.72, 75% percentile 166; neurons with pathology 
(NWP), 25% percentile 98.9, median 121.044, 75% percentile 169.4; p value = 0.36) and 
CII70 in neurons both with and without alpha-synuclein pathology (NWOP; 25% percentile 
93.8, median 121.45, 75% percentile 179; NWP; 25% percentile 105.1, median 126.96, 75% 
percentile 184.7; p value = 0.15). Part B: Staining intensities for Complex I subunits in 
individual SN neurons both with and without pathology (CI19 NWOP; 25% percentile 74.8, 
median 102.58, 75% percentile 127.7; NWP; 25% percentile 103.1, median 127.03, 75% 
percentile 183.3, CI20 NWOP; 25% percentile 32.3, median 72.03, 75% percentile 120.9; 
NWP; 25% percentile 87.1, median 115.23, 75% percentile 136)  Part C: Staining intensities 
for Complex IV subunits in individual SN (COXI NWOP; 25% percentile 90.5, median 
113.73, 75% percentile 133.1; NWP; 25% percentile 123.2, median 139.88, 75% percentile 
157.3, COXIV NWOP; 25% percentile 77.2, median 93.89, 75% percentile 109.2; NWP; 
25% percentile 91, median 103.58, 75% percentile 127.3). * - p value = < 0.0001. The 
median of each data set is shown (bar), the data has been normalised to the mean staining 
intensity for the control data and each data point represents one neuron. 
 
The mean mitochondrial CI19 staining increases in neurons containing alpha-synuclein 
pathology compared to those without pathology for 11/12 cases. For LBD6 there is a very 
small decrease in staining intensity in cells with pathology compared to those without 
pathology, but this may be explained by the small sample size when considering individual 
cases.  LBD- Lewy body disease.  
Figure 4. Mitochondrial complex I 19kDa subunit staining is increased in neurons containing 
alpha-synuclein pathology in all cases. 
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 The level of mitochondrial protein varies little between neurons containing different amounts 
of alpha-synuclein pathology. Part A; Results from neurons stained for CI19. * p value = 
<0.001, ** p value =<0.05. Part B; Results for COXI. The median of each data set is shown 
(bar), each data point represents one neuron. 
Figure 5. The increase in mitochondrial protein staining is not related to the extent of alpha-
synuclein pathology present within single neurons. 
 
Figure 6. Distributions of staining intensity of complex I in SN neurons of controls and LBD 
cases.
Percentage of SN neurons which fall into each of the 10% staining intensity brackets, for 
Lewy body disease case neurons, compared to controls and only those with pathology. Note 
that neurons with a staining intensity in the bottom 10% of this range were defined as 
deficient. A; Complex I 20kDa subunit, B; Complex I 19kDa subunit. C-E; examples of 
neurons stained with different intensities throughout the range of complex I 20kDa, C- 
intense staining, D-moderate staining, E-weak (deficient) staining. Scale bars represent 
20µm.   
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Table to show the cell loss and cortical Lewy body scores for all LBD patients used in this 
study, along with their clinical diagnosis. The cortical Lewy body score for each individual is 
assessed from the whole cortical area samples/available from each case. Cell loss scores 0/4 
(0-25%), 1/4 (25-50%), 2/4 (50-75%), 4/4 (75-100%).  UMB – upper midbrain, LMB – lower 
midbrain. 
Table 1.  Clinical and neuropathological features of all DLB and PD cases used in this study.  
Case Disease Cortical Lewy body 
score (cLB) 
SN cell loss 
1 DLB 19 UMB = 2/4 
LMB =3/4 
2 DLB 11 UMB = 2/4 
LMB =3/4 
3 DLB 17 UMB = 2/4 
LMB =3/4 
4 DLB 10 UMB = 2/4 
LMB =3/4 
5 DLB 16 UMB = 2/4 
LMB =2/4 
6 DLB 6 (Limbic) UMB = 2/4 
LMB =4/4 
7 DLB 17 (neocortex) UMB = 1-2/4 
8 DLB 19 UMB = 2/4 
LMB =3/4 
1 PD 13 UMB = 2/4 
2 PD 1 (brainstem) UMB = 1/4 
LMB =1/4 
3 PD 11 UMB = 3/4 
LMB =2/4 
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4 Mixed PD (with 
cerebral amyloid 
angiopathy) 
11 UMB = 1/4 
LMB =4/4 
5 PDD NA (severe cortical 
pathology) 
UMB = 2-3/4 
LMB =2-3/4 
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Supplementary tables and figures. 
Supplementary figure  1. Consistency of staining.
The mean (bars) and distributions of staining intensities for porin in individual SN neurons 
are consistent between Lewy body disease (Part A) and normal control cases (part B) (data 
was normalised to the mean staining for porin).  Each data point represents one neuron. Part 
C: Pooled data from A & B, means and ranges of staining intensities show no difference 
between all controls and DLB cases (p value = 0.58).  
  
 
Images of cerebellar Purkinje cells from a patient with the m.3243A>G mutation. COX/SDH 
histochemistry of frozen sections shows clear evidence of respiratory deficiency (blue cells) 
and normal activity (brown cells) (parts A and B).  In fixed sections from the same patient, 
cells lacking mitochondrial proteins or which show reduced amounts of protein are clearly 
detected (red arrow) with some cells showing normal protein expression (blue arrows) (parts 
C-F). This difference shown by eye is matched by the densitometry values (part G).  
Supplementary figure 2. Immunohistochemistry for mitochondrial proteins compares with 
COX/SDH histochemistry. 
 
Distribution of mitochondrial protein staining intensities in SN neurons from normal controls. 
The data presented is from cells without alpha synuclein pathology. Note the skewed 
distribution of staining intensities for CI19. The median of each data set is shown (bar) and 
each data point represents one neuron. 
Supplementary figure  3. Mitochondrial protein staining shows a large variation in normal 
controls. 
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Table to show the antibody dilutions required for the mitochondrial protein primary 
antibodies (Mitosciences, Oregon, USA) when used in conjunction with the Menapath 
polymer system. 
Supplementary Table 1. Details of antibodies used in this study. 
 
Mitochondrial 
protein 
 
Subunit specificity Mouse 
McAb 
clone 
Catalogue number Dilution 
 
Porin 
 
 
VDAC 20B12AF2 MAS03 
 
1:10,000 
 
Complex I 
 
 
19kDa 
(CI19, NDUFA13, 
GRIM-19) 
6E1BH7 MS103 
 
1:3,000 
 
Complex I 
 
 
20kDa 
(CI20, NDUFB8) 
20E9DH10C12 MS105 
 
1:300 
 
Complex II 
 
 
70kDa 
CII70, flavoprotein 
2E3GC12FB2AE2 MS204 
 
1:5,000 
 
Complex IV 
 
 
Subunit I 
(COXI) 
1D6E1A8 MS404 
 
1:10,000 
 
Complex IV 
 
 
Subunit IV 
(COXIV) 
 
10G8D12C12 MS408 
 
1:8,000 
 
